AB64. Meta-analysis of adjuvant chemotherapy on the prognosis for gastric cancer patients after D2 dissection
Abstract

AB64. Meta-analysis of adjuvant chemotherapy on the prognosis for gastric cancer patients after D2 dissection

Guanggai Xia, Changhua Zhang, Zhewei Wei, Ying Wu, Yulong He

Department of Gastrointestinopancreatic Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510089, China

Objective: To evaluate efficacy of adjuvant chemotherapy after D2 dissection on the survival for patients with gastric cancer.

Methods: Randomized clinical trials (RCTs) that compared adjuvant chemotherapy after D2 dissection with D2 dissection alone for gastric cancer were searched with Pubmed, Cochrane, Embase and CBM databases. Eligible trials published between 1990 and 2012 were included in the study. The quality of RCTs was assessed by the Jadad scale. Data synthesis and statistical analysis were performed by RevMan 5.1 software.

Results: Eight RCTs with 3,633 patients were included in this study. Among them, 1,824 patients received adjuvant chemotherapy and 1,809 patients didn’t. Adjuvant chemotherapy was associated with a significant benefit in terms of overall survival (RR=0.76; 95% CI, 0.69-0.84), disease free survival (RR=0.72; 95% CI, 0.66-0.80) and recurrence rate (RR=0.69; 95% CI, 0.62-0.77).

Conclusions: Adjuvant chemotherapy is associated with survival benefit for gastric cancer after D2 dissection.

Keywords: Adjuvant chemotherapy; D2 dissection; stomach neoplasms; meta-analysis

Cite this abstract as: Xia GG, Zhang CH, Wei ZW, Wu Y, He YL. Meta-analysis of adjuvant chemotherapy on the prognosis for gastric cancer patients after D2 dissection. Transl Gastrointest Cancer 2013;2(S1):AB64. doi: 10.3978/j.issn.2224-4778.2013.s064